Patents by Inventor Jiandie Lin
Jiandie Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9878010Abstract: Methods of treating metabolic and/or lipid disorders are provided comprising administering to a patient in need thereof a therapeutically effective amount of Nrg4, an Nrg4 variant, or a biologically active fragment thereof.Type: GrantFiled: March 19, 2014Date of Patent: January 30, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jiandie Lin, Guoxiao Wang
-
Publication number: 20160279201Abstract: Methods of treating metabolic and/or lipid disorders are provided comprising administering to a patient in need thereof a therapeutically effective amount of Nrg4, an Nrg4 variant, or a biologically active fragment thereof.Type: ApplicationFiled: March 19, 2014Publication date: September 29, 2016Applicant: THE REGENTS OF UNIVERSITY OF MICHIGANInventors: Jiandie Lin, Guoxiao Wang
-
Patent number: 8889639Abstract: The present invention provides methods for treating lipid-related diseases and disorders, e.g., hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, cardiovascular disease, obesity, and type II diabetes, and for modulating lipid biosynthesis, lipid transport, plasma triglyceride levels and/or plasma cholesterol levels, by modulating the expression or activity of PGC-1?. Methods for identifying compounds which are capable of treating or preventing a lipid-related disease or disorder are also described.Type: GrantFiled: October 21, 2005Date of Patent: November 18, 2014Assignees: Dana-Farber Cancer Institute, Inc., Duke UniversityInventors: Bruce M. Spiegelman, Jiandie Lin, Christopher B. Newgard
-
Patent number: 8445233Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 21, 2011Date of Patent: May 21, 2013Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Publication number: 20120167240Abstract: The present invention provides methods for modulating mitochondrial function, modulating lesion formation in the brain, modulating neurite growth, modulating neuronal degeneration, and treating and preventing neurological diseases or disorders comprising modulating the expression of activity of PGC-1?. The present invention also provides an animal, e.g., transgenic mouse, in which the PGC-1? gene is misexpressed. Methods for identifying compounds which are capable of treating or preventing a neurological disease or disorder are also described.Type: ApplicationFiled: April 12, 2011Publication date: June 28, 2012Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Jiandie Lin, Bruce M. Spiegelman
-
Publication number: 20120094293Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: BRUCE M. SPIEGELMAN, JIANDIE LIN
-
Patent number: 8105774Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 10, 2008Date of Patent: January 31, 2012Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Patent number: 7947652Abstract: The present invention provides methods for modulating mitochondrial function, modulating lesion formation in the brain, modulating neurite growth, modulating neuronal degeneration, and treating and preventing neurological diseases or disorders comprising modulating the expression or activity of PGC-1?. The present invention also provides an animal, e.g., transgenic mouse, in which the PGC-1? gene is misexpressed. Methods for identifying compounds which are capable of treating or preventing a neurological disease or disorder are also described.Type: GrantFiled: September 6, 2005Date of Patent: May 24, 2011Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Jiandie Lin, Bruce M. Spiegelman
-
Publication number: 20090005314Abstract: The present invention provides methods for modulating mitochondrial function, modulating lesion formation in the brain, modulating neurite growth, modulating neuronal degeneration, and treating and preventing neurological diseases or disorders comprising modulating the expression or activity of PGC-1?. The present invention also provides an animal, e.g., transgenic mouse, in which the PGC-1? gene is misexpressed. Methods for identifying compounds which are capable of treating or preventing a neurological disease or disorder are also described.Type: ApplicationFiled: September 6, 2005Publication date: January 1, 2009Inventors: Jiandie Lin, Bruce M. Spiegelman
-
Publication number: 20080261224Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: March 10, 2008Publication date: October 23, 2008Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Publication number: 20080206232Abstract: The present invention provides methods for treating lipid-related diseases and disorders, e.g., hyperlipidemia, hyper-triglyceridemia, hypercholesterolemia, cardiovascular disease, obesity, and type II diabetes, and for modulating lipid biosynthesis, lipid transport, plasma triglyceride levels and/or plasma cholesterol levels, by modulating the expression or activity of PGC-1?. Methods for identifying compounds which are capable of treating or preventing a lipid-related disease or disorder are also described.Type: ApplicationFiled: October 21, 2005Publication date: August 28, 2008Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin, Christopher B. Newgard
-
Patent number: 7354738Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: April 27, 2006Date of Patent: April 8, 2008Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Publication number: 20070009933Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: April 27, 2006Publication date: January 11, 2007Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Bruce Spiegelman, Jiandie Lin
-
Patent number: 7091006Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 8, 2002Date of Patent: August 15, 2006Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Publication number: 20060035849Abstract: The invention provides novel methods and compositions for modulating type I muscle formation through modulation of PGC-1? activity or expression. Also provided are methods for identifying compounds that modulate type I muscle formation through modulation of PGC-1? activity or expression. Further provided are methods for treating disorders associated with type I and/or type II muscle formation, as well as transgenic animals expressing PGC-1? in muscle.Type: ApplicationFiled: February 13, 2003Publication date: February 16, 2006Applicant: DanaFarber Cancer Institute, IncInventors: Bruce Spiegelman, Jiandie Lin
-
Publication number: 20030124598Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1&bgr; nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1&bgr; nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1&bgr; gene has been introduced or disrupted. The invention still further provides isolated PGC-1&bgr; proteins, fusion proteins, antigenic peptides and anti-PGC-1&bgr; antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: November 8, 2002Publication date: July 3, 2003Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Patent number: 6261841Abstract: The invention includes compositions, kits, and methods for modulating survival and differentiation of mammalian multi-potential hematopoietic progenitor cells using a placental glycoprotein hormone of the murine prolactin family, namely either murine prolactin-like protein E or murine prolactin-like protein F. The compositions, kits, and methods described herein can be used, for example, for in vitro or ex vivo expansion of hematopoietic precursor cells or to treat a disorder associated with aberrant hematopoiesis (e.g., pre-eclampsia and thrombocytopenia).Type: GrantFiled: June 23, 2000Date of Patent: July 17, 2001Assignee: The Board of Trustees of Northwestern UniversityInventors: Isaac Cohen, Phil Lefebvre, Jiandie Lin, Daniel Linzer